Tune in to this Nucleate podcast for an in-depth chat with Dyno Founder and CEO Eric Kelsic (he/him) including a conversation about Dyno’s origins, and how collaboration and curiosity are essential to identifying high-impact scientific projects.

Pleased to share that our CEO and cofounder Eric Kelsic (he/him) was highlighted among the Top 50 Healthcare AI Entrepreneurs of 2025 👉 thegreatentrepreneurs.com/the-top-50-hea…

Our CEO Eric Kelsic (he/him) sat down with NYSE 🏛 to share his thoughts about where the future of healthcare is heading, and what it means for gene therapy patients. 👉 nyse.com/insights/the-c…

Don’t miss our co-founder Sam Sinai’s talk at #GTC2025! Sam will share Dyno’s latest progress on LEAP—our technology bridging foundation models and therapeutic impact—and demo DynoFold, a new AI model powered by NVIDIA AI that efficiently predicts protein dynamics directly from

Dyno is back at #ASGCT2025: three oral presentations and a Scientific Symposium detailing new optimized AAV capsids for CNS, eye and neuromuscular delivery, plus the state of the art AI models powering their design. Don’t miss it! More info: dynotx.com/dyno-therapeut…

Be sure to catch Dyno at #SynBioBeta2025 next week! Our CEO & Cofounder Eric Kelsic will be giving a talk and speaking on a panel highlighting what is possible at the intersection of AI and gene therapy, and what this means for the future of human health.

TOMORROW: Join us at this year’s #ASGCT25 Dyno Symposium! Dyno CEO & Cofounder Eric Kelsic will share data on leading-edge AAV capsids, the frontier AI models behind their design, and how Dyno supports partners rapidly advancing next-generation gene therapies into the clinic.

Join us tomorrow at #ASGCT25 for a presentation on the data behind Dyno’s newest CNS vector: an AI-designed AAV capsid optimized for widespread IV delivery to the brain, with exceptional liver detargeting and a highly conserved mechanism for blood-brain barrier crossing.

Today at the #ASGCT25 Dyno Symposium we announced the launch of three exceptional new capsids for gene delivery to the CNS, eye, and muscle: Dyno-ahq, Dyno-4z2 and Dyno-3hv. You can learn more about these capsids and partnering with Dyno at dynotx.com/gene-delivery, and as

Save the date! Today, Dyno announced the inaugural Genetic Agency Technology Conference (GATC) will take place on November 11th, 2025 in Boston. This one-day gathering will convene technical thought leaders, gene therapy developers, patients, their families, and patient

Today, we announced the Dyno Frontiers Program, an initiative designed to demonstrate the transformative therapeutic potential of innovative genetic payloads. The new Dyno Frontiers Program offers therapeutic developers access to Dyno’s gene delivery technology and scientific

Here’s a recap of the data we presented at #ASGCT25 this afternoon on our newest brain capsid: Dyno-ahq! As shared by Dr Mugdha Deshpande in her talk, Dyno-ahq is a breakthrough capsid for CNS delivery, with pan-brain tropism and exceptional liver detargeting. You can learn more

Don’t miss tomorrow’s #ASGCT25 presentation on Dyno’s newest ocular capsid, Dyno-4z2: an AI-designed AAV capsid with highly efficient delivery to the retina through intravitreal injection, with field-leading targeting of bipolar cells in the inner nuclear layer. ►Presenter:

Join us this Saturday at #ASGCT25 for a presentation on our new vector for neuromuscular gene delivery, Dyno-3hv: the first capsid of its kind optimized for highly efficient delivery to the multiple tissues affected by neuromuscular disorders, including heart, skeletal muscle and

Here’s a recap of the data we presented at #ASGCT25 this afternoon on our newest eye capsid: Dyno-4z2! As shared by Dr Amanda Miles in her talk, Dyno-4z2 is a breakthrough capsid for ocular delivery, with highly efficient delivery to the retina through intravitreal injection,

Tune into this episode of @BiotechTVHQ at #ASGCT25, where @BradLoncar and Eric Kelsic talk more in depth about the science behind the CNS, eye, and neuromuscular capsids we launched this week, as well as the Dyno Frontiers Program and upcoming GATC conference, and how they’re

Here’s a recap of the data we presented at #ASGCT25 this afternoon on our newest neuromuscular capsid: Dyno-3hv! As shared by Dr Megan Cramer in her talk, Dyno-3hv is the first capsid of its kind optimized for highly efficient delivery to the multiple tissues affected by

That’s a wrap on #ASGCT25! We had a great time sharing our latest scientific progress and initiatives—from the launch of three new capsids for CNS, eye, and neuromuscular targeting, to the announcement of the Dyno Frontiers Program and our upcoming GATC conference this fall.

Join us on June 3rd for our #NYTechWeek fireside chat where NVIDIA's Director of Digital Biology Anthony Costa and Dyno's CEO & Cofounder Eric Kelsic (he/him) will be discussing the next frontiers of AI in biology– from opportunities to real-world challenges. Reserve your spot here: